Document Detail

Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution.
MedLine Citation:
PMID:  19525858     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Small intestinal bacterial overgrowth (SIBO) may mimic a functional disorder such as irritable bowel syndrome (IBS) or functional bloating (FB). In this study, we aimed to assess the utility of glucose breath test (GBT) in patients with the above conditions. METHODS: This study included 200 consecutive patients (130 with IBS and 70 with FB on the basis of Rome III criteria) and 70 controls with similar age and sex distribution. Patients and controls underwent 50 g GBT and a H2 peak of > or = 12 ppm was considered diagnostic of SIBO. Positive patients received rifaximin of 1200mg/day for 10 days and underwent a second GBT 1 month after the end of treatment. A symptom questionnaire was completed before and after therapy. RESULTS: GBT resulted to be altered in 21 out of 130 IBS patients and in 2 out of 70 FB patients with a significant difference of the former group compared with controls (3 out of 70, P=0.0137). Most IBS patients with a positive GBT complained of diarrhea. GBT showed an increased methane excretion in 26% of patients, who were equally distributed among different bowel pattern subgroups. Previous abdominal surgery was more frequently seen in GBT-positive patients (P=0.008). After antibiotic treatment, eradication of SIBO was achieved in 70% of patients, with a significant improvement of symptoms in eradicated patients compared with the not eradicated ones (P<0.001). CONCLUSIONS: GBT is useful to identify a subgroup of IBS-like patients, whose symptoms are owing to SIBO. Normalization of GBT after antibiotic therapy is associated with a significant improvement of symptoms. GBT does not offer any advantage in FB patients.
Andrea Parodi; Pietro Dulbecco; Edoardo Savarino; Edoardo Giovanni Giannini; Giorgia Bodini; Marina Corbo; Luca Isola; Stefano De Conca; Elisa Marabotto; Vincenzo Savarino
Related Documents :
7276488 - The right iliac fossa squelch sign: a marker of the irritable bowel syndrome.
8491898 - Intestinal infarction secondary to mesenteric venous thrombosis: ct-pathologic correlat...
8291278 - Intestinal absorption and malnutrition in patients with the acquired immunodeficiency s...
21288688 - The use of gadolinium for arterial interventions.
16900308 - Esophageal diverticula: pathogenesis, clinical aspects, and natural history.
12138988 - Spine abnormalities and damage in patients cured from cushing's disease.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of clinical gastroenterology     Volume:  43     ISSN:  1539-2031     ISO Abbreviation:  J. Clin. Gastroenterol.     Publication Date:    2009 Nov-Dec
Date Detail:
Created Date:  2009-10-26     Completed Date:  2010-01-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7910017     Medline TA:  J Clin Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  962-6     Citation Subset:  IM    
Department of Internal Medicine, University of Genoa, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Bacterial Agents / therapeutic use
Breath Tests / methods
Gastric Dilatation / diagnosis*,  microbiology
Glucose / diagnostic use
Intestine, Small / microbiology*
Irritable Bowel Syndrome / diagnosis*,  microbiology
Methane / metabolism
Middle Aged
Rifamycins / therapeutic use
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Rifamycins; 50-99-7/Glucose; 74-82-8/Methane; 88747-56-2/rifaximin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Laparoscopic approach for urgent abdominal surgery in patients with left ventricular assist devices.
Next Document:  Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease.